2-Bromo-5-(trifluoromethoxy)pyridine: Handling & Use Protocol

2-Bromo-5-(trifluoromethoxy)pyridine is a versatile halopyridine building block widely employed in palladium-catalyzed cross-coupling reactions and pharmaceutical synthesis owing to its electron-withdrawing trifluoromethoxy substituent and reactive C–Br bond.

CAS Number

845618-21-5

Molecular Formula

C6H3BrF3NO

Molecular Weight

242.00 g/mol

Appearance

Colorless to pale yellow liquid or low-melting solid

Key Functional Groups

Aryl bromide, trifluoromethoxy (–OCF3), pyridine nitrogen

Primary Applications

Suzuki, Miyaura, Buchwald–Hartwig couplings; medicinal chemistry

Safety and Storage

2-Bromo-5-(trifluoromethoxy)pyridine should be handled with standard laboratory precautions for halogenated aromatic compounds. Work in a well-ventilated fume hood and wear appropriate personal protective equipment (PPE) including nitrile gloves, safety goggles, and a lab coat. Avoid inhalation of vapors and contact with skin or eyes.

Store the compound in a tightly sealed container under an inert atmosphere (nitrogen or argon) at 2–8 °C, protected from light and moisture. When stored correctly, the reagent is stable for at least 24 months. Consult the Safety Data Sheet (SDS) for full hazard classification, first-aid measures, and disposal guidance before use.

Solution Preparation

2-Bromo-5-(trifluoromethoxy)pyridine is soluble in common organic solvents including tetrahydrofuran (THF), dichloromethane (DCM), dimethylformamide (DMF), acetonitrile, and toluene. It has limited solubility in water.

General procedure:

1. Allow the sealed container to equilibrate to room temperature before opening to prevent condensation of atmospheric moisture.
2. Weigh the required amount of reagent rapidly in air or, for moisture-sensitive downstream reactions, under inert gas using a glovebox or Schlenk technique.
3. Dissolve in the chosen anhydrous solvent at the desired concentration (typical stock concentrations: 0.1–1.0 M).
4. Use freshly prepared solutions where possible; if storage is required, seal under inert gas at –20 °C and use within 4 weeks.

Cross-Coupling Reaction Protocol

The C–Br bond in 2-Bromo-5-(trifluoromethoxy)pyridine undergoes efficient palladium-catalyzed cross-coupling reactions. The following represents a general Suzuki–Miyaura coupling procedure.

Reagents and conditions:

• 2-Bromo-5-(trifluoromethoxy)pyridine (1.0 equiv)
• Arylboronic acid (1.2–1.5 equiv)
• Pd(PPh3)4 or Pd(dppf)Cl2 (2–5 mol%)
• Base: K2CO3 or Cs2CO3 (2.0–3.0 equiv)
• Solvent: DMF/H2O (4:1) or dioxane/H2O (4:1)
• Temperature: 80–100 °C, 12–18 h under inert atmosphere

Procedure:

1. Charge a Schlenk flask or sealed tube with the arylboronic acid, base, and catalyst under N2 or Ar.
2. Add a solution of 2-Bromo-5-(trifluoromethoxy)pyridine in the chosen solvent system.
3. Degas the reaction mixture by three freeze–pump–thaw cycles or by sparging with inert gas for 10 min.
4. Heat the reaction mixture at the specified temperature with stirring until consumption of starting material (monitored by TLC or LC-MS).
5. Cool to room temperature, dilute with ethyl acetate, wash with brine, dry over Na2SO4, filter, and concentrate under reduced pressure.
6. Purify the crude product by column chromatography (silica gel, hexane/ethyl acetate gradient).

Note: The electron-deficient nature of the pyridine ring, reinforced by the –OCF3 group, can facilitate nucleophilic aromatic substitution (SNAr) at C-2 under appropriate conditions (strong nucleophile, polar aprotic solvent, elevated temperature) as an alternative synthetic route.

Quality Control and Analytical Characterization

Confirm the identity and purity of 2-Bromo-5-(trifluoromethoxy)pyridine and its reaction products using the following analytical techniques:

• 1H NMR (400 MHz, CDCl3): Expected signals for the pyridine ring protons at approximately δ 8.3 (d, H-6), 7.6 (dd, H-4), and 7.4 (d, H-3) ppm. Exact chemical shifts should be verified against the certificate of analysis (CoA).
• 19F NMR: A characteristic singlet for the –OCF3 group is expected near δ –58 ppm (relative to CFCl3).
• GC or HPLC purity: Purity ≥98% (as specified on the CoA for Aladdin SKU B195611).
• Mass Spectrometry (EI or ESI): Expected [M]+ or [M+H]+ consistent with MW 242.00 g/mol; the characteristic isotope pattern for one bromine atom (M:M+2 ≈ 1:1) confirms the presence of the aryl bromide.

Always compare results against the product CoA supplied with each lot. Contact Aladdin Scientific technical support if analytical data fall outside specification.

Troubleshooting

The following table summarizes common issues encountered when working with 2-Bromo-5-(trifluoromethoxy)pyridine and recommended corrective actions:

• Low coupling yield: Ensure complete degassing of the reaction mixture; check catalyst activity and loading; consider switching to a more active palladium catalyst (e.g., Pd2(dba)3 with a bulky phosphine ligand such as SPhos or XPhos).
• Protodebromination side product: Reduce reaction temperature or time; minimize water content in the solvent system; use a milder base.
• Reagent decomposition: Verify storage conditions; confirm that the container was properly resealed under inert gas after each use.
• Poor solubility of boronic acid coupling partner: Switch to the corresponding boronic acid pinacol ester (Bpin) or potassium trifluoroborate salt, which often offer improved stability and solubility.
• Color change or turbidity in stock solution: Discard the solution and prepare a fresh batch; discoloration may indicate partial decomposition or contamination.

Frequently asked questions

What palladium catalysts are recommended for Suzuki coupling with 2-Bromo-5-(trifluoromethoxy)pyridine?

Pd(PPh3)4 and Pd(dppf)Cl2 are commonly used starting points. For challenging substrates or when higher activity is required, Pd2(dba)3 combined with a bulky monodentate phosphine ligand such as SPhos or XPhos is recommended. Catalyst loading is typically 2–5 mol%.

How should I store 2-Bromo-5-(trifluoromethoxy)pyridine to maintain its stability?

Store the compound in a tightly sealed container under an inert atmosphere (nitrogen or argon) at 2–8 °C, protected from light and moisture. Under these conditions the reagent is expected to remain stable for at least 24 months. Always reseal the container promptly after use.

Can 2-Bromo-5-(trifluoromethoxy)pyridine undergo nucleophilic aromatic substitution (SNAr)?

Yes. The combined electron-withdrawing effects of the pyridine nitrogen and the –OCF3 group activate the C-2 position toward SNAr with strong nucleophiles such as amines, alkoxides, or thiolates under polar aprotic conditions at elevated temperatures. This provides a complementary route to cross-coupling for the introduction of heteroatom-based substituents.

What is the significance of the –OCF3 group in medicinal chemistry applications?

The trifluoromethoxy group (–OCF3) is a bioisostere valued in drug design for its strong electron-withdrawing character, high lipophilicity (π = +1.04), and metabolic stability. Incorporation of –OCF3 into drug candidates can improve membrane permeability and metabolic resistance compared with unsubstituted or methoxy-bearing analogs.

Which solvents are suitable for dissolving 2-Bromo-5-(trifluoromethoxy)pyridine?

The compound is freely soluble in common organic solvents including THF, DCM, DMF, acetonitrile, and toluene. It has poor solubility in water. For cross-coupling reactions, mixed aqueous-organic solvent systems (e.g., dioxane/H2O or DMF/H2O) are often employed to solubilize both the organic substrate and inorganic base.

References

1. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457–2483. doi:10.1021/cr00039a007
2. Hansch, C.; Leo, A.; Taft, R. W. A survey of Hammett substituent constants and resonance and field parameters. Chem. Rev. 1991, 91, 165–195. doi:10.1021/cr00002a004
3. Leroux, F. R.; Manteau, B.; Vors, J.-P.; Pazenok, S. Trifluoromethyl ethers — synthesis and properties of an unusual substituent. Beilstein J. Org. Chem. 2008, 4, No. 13. doi:10.3762/bjoc.4.13

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.